Polymerase I as a Target for Treating Neurodegenerative Disorders DOI Open Access
Mark S. LeDoux

Published: April 4, 2024

Polymerase I (Pol I) is at the epicenter of ribosomal RNA (rRNA) synthesis. Pol a target for treatment cancer. Given many cellular commonalities between cancer and neurodegeneration (i.e., different faces same coin) it seems rational to consider targeting or, more generally, rRNA synthesis disorders associated with death terminally differentiated neurons. Principally, ribosomes synthesize proteins and, accordingly, can be considered starting point protein that accumulation abnormal such as α-synuclein tau an essential feature neurodegenerative Parkinson disease fronto-temporal dementia, reduction production now viable these closely related disorders. Abnormalities in polymerase activity may also nuclear nucleolar stress, DNA damage, childhood onset neuronal case UBTF E210K neuroregression syndrome. Moreover, restraining strategy slow aging. Before down road inhibition treating non-cancerous nervous system, questions must answered. First, how much neurons tolerate long? Should continuous or pulsed? Will cells compensate by upregulating number active rDNAs? At present, we have no effective safe modulatory treatments Alzheimer disease, α-synucleinopathies, tauopathies, novel therapeutic targets approaches explored.

Language: Английский

Evolving Landscape of Parkinson’s Disease Research: Challenges and Perspectives DOI Creative Commons
Rumiana Koynova, Janet M. Sasso, Qiongqiong Angela Zhou

et al.

ACS Omega, Journal Year: 2025, Volume and Issue: 10(2), P. 1864 - 1892

Published: Jan. 8, 2025

Parkinson's disease (PD) is a progressive neurodegenerative disorder that primarily affects movement. It occurs due to gradual deficit of dopamine-producing brain cells, particularly in the substantia nigra. The precise etiology PD not fully understood, but it likely involves combination genetic and environmental factors. therapies available at present alleviate symptoms do stop disease's advancement. Research endeavors are currently directed inventing disease-controlling aim inherent mechanisms PD. biomarker breakthroughs hold enormous potential: earlier diagnosis, better monitoring, targeted treatment based on individual response could significantly improve patient outcomes ease burden this disease. research an active evolving field, focusing understanding mechanisms, identifying biomarkers, developing new treatments, improving care. In report, we explore data from CAS Content Collection outline progress We analyze publication landscape offer perspective into latest expertise advancements. Key emerging concepts reviewed strategies fight evaluated. Pharmacological targets, risk factors, as well comorbid diseases explored, clinical usage products against with their production pipelines trials for drug repurposing examined. This review aims comprehensive overview advancing current about PD, define challenges, assess growth prospects stimulate efforts battling

Language: Английский

Citations

3
Emerging Trends: Neurofilament Biomarkers in Precision Neurology DOI
Priti Sharma, Aditi Giri, Prabhash Nath Tripathi

et al.

Neurochemical Research, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 30, 2024

Language: Английский

Citations

5
Moderators of Aerobic Exercise Effects on Motor Symptoms in Patients with Parkinson's Disease: A Systematic Review and Meta-analysis DOI
Ryul Kim, Nyeonju Kang, Joon Ho Lee

et al.

Parkinsonism & Related Disorders, Journal Year: 2025, Volume and Issue: unknown, P. 107779 - 107779

Published: March 1, 2025

Language: Английский

Citations

0
Prodromal Parkinson’s Disease DOI
Iro Boura, Karolina Popławska-Domaszewicz,

Naomi Limbachiya

et al.

Neurologic Clinics, Journal Year: 2025, Volume and Issue: 43(2), P. 209 - 228

Published: Jan. 22, 2025

Language: Английский

Citations

0
GM1 Ganglioside as a Disease-Modifying Therapeutic for Parkinson’s Disease: A Multi-Functional Glycosphingolipid That Targets Multiple Parkinson’s Disease-Relevant Pathogenic Mechanisms DOI Open Access
Jay S. Schneider

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(11), P. 9183 - 9183

Published: May 24, 2023

Parkinson's disease (PD) is a progressive neurodegenerative disorder affecting millions of patients worldwide. Many therapeutics are available for treating PD symptoms but there no disease-modifying therapeutic that has been unequivocally shown to slow or stop the progression disease. There several factors contributing failure many putative agents in clinical trials and these include choice trial designs modification trials. Perhaps more important, however, therapeutic, which most part, not taken into account multiple complex pathogenic mechanisms processes involved PD. This paper discusses some lack success disease-modification trials, have mostly investigated with singular mechanism action directed at one processes, suggests an alternative strategy may be employ multi-functional target PD-relevant mechanisms. Evidence presented glycosphingolipid GM1 ganglioside just such therapeutic.

Language: Английский

Citations

3
Polymerase I as a Target for Treating Neurodegenerative Disorders DOI Creative Commons
Mark S. LeDoux

Biomedicines, Journal Year: 2024, Volume and Issue: 12(5), P. 1092 - 1092

Published: May 15, 2024

Polymerase I (Pol I) is at the epicenter of ribosomal RNA (rRNA) synthesis. Pol a target for treatment cancer. Given many cellular commonalities between cancer and neurodegeneration (i.e., different faces same coin), it seems rational to consider targeting or, more generally, rRNA synthesis disorders associated with death terminally differentiated neurons. Principally, ribosomes synthesize proteins, and, accordingly, can be considered starting point protein that accumulation abnormal proteins such as α-synuclein tau an essential feature neurodegenerative Parkinson disease fronto-temporal dementia, reduction production now viable these closely related disorders. Abnormalities in polymerase activity may also nuclear nucleolar stress, DNA damage, childhood-onset neuronal death, case UBTF E210K neuroregression syndrome. Moreover, restraining strategy slow aging. Before down road inhibition treating non-cancerous nervous system, questions must answered. First, how much neurons tolerate, long? Should continuous or pulsed? Will cells compensate by upregulating number active rDNAs? At present, we have no effective safe modulatory treatments Alzheimer disease, α-synucleinopathies, tauopathies, novel therapeutic targets approaches explored.

Language: Английский

Citations

0
Effects of a Cocktail Supplement of Ginkgo Biloba and Acai Extract on Cognitive Symptoms of Parkinson’s Disease DOI Open Access

Yulia Dubrovensky

Advances in Parkinson s Disease, Journal Year: 2024, Volume and Issue: 13(03), P. 57 - 72

Published: Jan. 1, 2024

Parkinson's Disease (PD) is a neurodegenerative disorder characterized by motor and non-motor symptoms, including cognitive impairment. Current treatments often involve synthetic drugs with significant side effects potential for dependency. This study investigates the of natural supplement combination Ginkgo Biloba Acai Extract on symptoms in 77-year-old male PD. The participant underwent three-month supplementation regimen, function assessed using Montreal Cognitive Assessment (MoCA) test before after intervention. results indicated an improvement scores, suggesting that may offer promising alternative or adjunct to conventional PD treatments. highlights supplements managing calls further research larger sample sizes confirm these findings. Human data was performed accordance Declaration Helsinki Roxbury District IRB Board (IRB Number: IRB00011767).

Language: Английский

Citations

0
Polymerase I as a Target for Treating Neurodegenerative Disorders DOI Open Access
Mark S. LeDoux

Published: April 4, 2024

Polymerase I (Pol I) is at the epicenter of ribosomal RNA (rRNA) synthesis. Pol a target for treatment cancer. Given many cellular commonalities between cancer and neurodegeneration (i.e., different faces same coin) it seems rational to consider targeting or, more generally, rRNA synthesis disorders associated with death terminally differentiated neurons. Principally, ribosomes synthesize proteins and, accordingly, can be considered starting point protein that accumulation abnormal such as α-synuclein tau an essential feature neurodegenerative Parkinson disease fronto-temporal dementia, reduction production now viable these closely related disorders. Abnormalities in polymerase activity may also nuclear nucleolar stress, DNA damage, childhood onset neuronal case UBTF E210K neuroregression syndrome. Moreover, restraining strategy slow aging. Before down road inhibition treating non-cancerous nervous system, questions must answered. First, how much neurons tolerate long? Should continuous or pulsed? Will cells compensate by upregulating number active rDNAs? At present, we have no effective safe modulatory treatments Alzheimer disease, α-synucleinopathies, tauopathies, novel therapeutic targets approaches explored.

Language: Английский

Citations

0